MDxHealth has already established a robust commercial platform for cancer diagnostics. Focussed on prostate and bladder cancer, MDxHealth's diagnostic tests relieve the clinical burden on the patient and economic burden on the health provider by reducing the need for the risky, expensive and often unnecessary procedures such as needle biopsies that are regularly performed on patients after a positive primary cancer screen. With sales of its first product growing strongly in the US, the company l ....
25 Oct 2016
Prostate cancer screening without the needle
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Prostate cancer screening without the needle
MDxHealth S.A. (0O8G:LON) | 0 0 0.3% | Mkt Cap: 168.5m
- Published:
25 Oct 2016 -
Author:
Chris Redhead -
Pages:
28
MDxHealth has already established a robust commercial platform for cancer diagnostics. Focussed on prostate and bladder cancer, MDxHealth's diagnostic tests relieve the clinical burden on the patient and economic burden on the health provider by reducing the need for the risky, expensive and often unnecessary procedures such as needle biopsies that are regularly performed on patients after a positive primary cancer screen. With sales of its first product growing strongly in the US, the company l ....